Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC) (ETOC)

December 2, 2009 updated by: Assistance Publique - Hôpitaux de Paris

Evaluation of Early Percutaneous Tracheostomy in Patients Undergoing Cardiovascular Surgery and Requiring Prolonged Mechanical Ventilation

This is a phase III clinical trial comparing early tracheostomy (day 4) versus prolonged endotracheal intubation in ICU patients needing prolonged ventilatory support after cardiovascular surgery.

Study Overview

Detailed Description

Background: Prolonged mechanical ventilation (MV> 7 days) is required in less than 10% of patients after cardiovascular surgery but it is associated with high morbidity and mortality.

Several studies conducted in critically ill patients suggested that early percutaneous tracheotomy compared with delayed tracheotomy decreases the length of ventilator dependence and improves outcome. To date, no randomized trial has tested these possible benefits in critically ill patients after cardiac surgery.

Study objectives: A randomized trial has been designed to determine whether early tracheostomy (day 4 after cardiac surgery) in patients still on MV would reduce the number of days under MV, measured by the evaluation of ventilator-free days (VFDs). Secondary objectives are the reduction of mortality, reduction of ICU and hospital length of stay. Evaluation of organ failure evolution, infectious complications, sedation needs, patient comfort and outcome at 3 months will be also considered.

Study hypothesis: The trial will be consider positive if early tracheotomy increases the number VFDs of at least 7 days (mean) evaluated on day 60 after randomisation.

Methods :

Trial : randomized, open, controlled, monocentric Inclusion criteria: see columns below Exclusion criteria: see columns below Randomization: will use a computerised system on day 4 after cardiac surgery Procedures: see columns below Recorded data: demographic characteristics, pre, per and postoperative parameters.

From randomization until ICU discharge (or day 60), a daily chart will be completed.

Judgment criteria: see columns below Sample size and statistical analysis: using Wilcoxon bilateral test with an alpha risk of 5% and a power of 80%, we calculated that 108 patients in each arm would be needed.

Statistical analyses will use standard tests to compare population of the two arms.

Study Type

Interventional

Enrollment (Actual)

212

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75013
        • Institut de Cardiologie - Chu Pitie Salpetriere Ap-Hp

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Are 18 years of age or older
  • Have undergone cardiovascular surgery
  • Are still on invasive mechanical ventilation on day 4 after surgery
  • Have failed the screening test or the spontaneous breathing trial
  • Have signed the informed consent (patient or legal representative)

Exclusion Criteria:

  • Age less than18
  • Pregnant woman
  • Intubation more than 48 hours before cardiovascular surgery
  • More than 5 days on mechanical ventilation after cardiac surgery
  • Artificial heart implantation
  • Concomitant neck surgery (carotid)
  • Previously tracheostomized
  • Major hemorrhagic risk
  • Persistence of platelet count less than 50.000/mm3 after platelet transfusion
  • Prothrombin time less than 30% despite coagulation factors administration
  • Clinical evidence of ongoing infection at the proposed tracheotomy site
  • Anatomical deformity of the neck making risky a tracheostomy
  • Probability of dying the day of randomization defined by SAPSII more than 80
  • Irreversible neurological lesions
  • Decision of care limitation
  • Prior inclusion in a trial with morbidity-mortality as main judgement criteria
  • Previous enrollment in this trial
  • Consent refusal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dilatational Percutaneous tracheostomy
Dilatational Percutaneous tracheostomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of ventilator-free days defined as the number of days between successful weaning from MV and day 60 after study enrolment.
Time Frame: between successful weaning from MV and day 60 after study enrolment.
between successful weaning from MV and day 60 after study enrolment.
VFDs = 0 if the patient dies before 60days.
Time Frame: before 60 days
before 60 days
VFDs= (60- X) : if the patient is successfully weaned from MV within 60 days, where X is the number of days spent receiving MV
Time Frame: during 60 days
during 60 days
VFDs = 0: if the patient requires MV for 60 days or more
Time Frame: during 60 days and after
during 60 days and after
The trial will be considered positive if early tracheostomy increases the number VFDs of at least 7 days (mean)
Time Frame: at 7 days
at 7 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Other outcomes will be compared between the two arms:
Time Frame: during the trial
during the trial
Mortality rate (day 60, in-ICU, in-hospital)
Time Frame: during the 60 days
during the 60 days
ICU length of stay
Time Frame: during the trial
during the trial
Hospital length of stay
Time Frame: during the trial
during the trial
Duration of MV in survivors
Time Frame: during the trial
during the trial
Organ failure evolution
Time Frame: during the trial
during the trial
Infectious complications
Time Frame: during the trial
during the trial
Early laryngeal and tracheal complications
Time Frame: during the trial
during the trial
Sedation needs
Time Frame: during the trial
during the trial
Patient comfort
Time Frame: during the trial
during the trial
Outcome on day 90
Time Frame: to 90 days
to 90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jean Louis TROUILLET, MD,, Assistance Publique - Hôpitaux de Paris

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2006

Primary Completion (Actual)

March 1, 2009

Study Completion (Actual)

June 1, 2009

Study Registration Dates

First Submitted

June 29, 2006

First Submitted That Met QC Criteria

June 29, 2006

First Posted (Estimate)

July 4, 2006

Study Record Updates

Last Update Posted (Estimate)

December 3, 2009

Last Update Submitted That Met QC Criteria

December 2, 2009

Last Verified

March 1, 2007

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Failure

Clinical Trials on Dilatational Percutaneous tracheostomy

3
Subscribe